Company Overview and News

Stephen Hawking fears Earth will turn into giant ball of fire by 2600

British scientist Stephen Hawking arrives to attend the launch of The Leverhulme Centre for the Future of Intelligence (CFI), at the University of Cambridge in Cambridge, eastern England, on Oct. 19, 2016. The CFI is a collaboration between the University of Cambridge, the University of Oxford, Imperial College London and the University of California, Berkeley.  AFP
Upvote Downvote

Kuehne & Nagel International's (KHNGF) CEO Detlef Trefzger on Q3 2017 Results - Earnings Call Transcript

2017-10-16 seekingalpha
Kuehne & Nagel International AG (OTCPK:KHNGF) Q3 2017 Results Earnings Conference Call October 16, 2017 8:00 AM ET
Upvote Downvote

TFI International's (TFIFF) CEO Alain Bédard on Q2 2017 Results - Earnings Call Transcript

2017-07-29 seekingalpha
TFI International, Inc (OTCQX:TFIFF) Q2 2017 Results Earnings Conference Call July 28, 2017 9:00 AM ET
Upvote Downvote

Government of Canada supports data-rich research

2016-09-15 marketwired
MONTREAL, QC--(Marketwired - September 15, 2016) - The Government of Canada understands the central role researchers play in making the discoveries and innovations necessary to explore the nature of the universe or understand the effects of noise pollution on marine life. To advance their experiments, many researchers need powerful computational tools and access to digital networks to rapidly process large amounts of data and quickly share results with collaborators across the country and around the world.
Upvote Downvote

New $13.2-million bone and joint health research facility opens at the Cumming School of Medicine

2016-09-08 marketwired
CALGARY, AB--(Marketwired - September 08, 2016) - A new centre for Mobility and Joint Health (MoJo) opened today that will allow researchers to develop new technologies for the prevention, early diagnosis and treatment of bone and joint conditions.
Upvote Downvote

How Bank of America Is Changing the World

2016-08-19 fortune
The staff of Fortune and a panel of experts recently named 50 companies to its 2016 Change the World list. Bank of America is one of them.
Upvote Downvote

Customer Satisfaction with Government Contact Centers Unchanged as Citizens Consider Interactive Voice Response Systems a Barrier

2016-07-12 prnewswire
Just 4% of IVR users got the information they needed from the automated system; telephone still most popular method of contact
Upvote Downvote

Government of Canada Support for Science Helps Attract Top Talent

2016-04-15 marketwired
OTTAWA, ON--(Marketwired - April 15, 2016) -  Researchers at Canadian universities play a central role in ensuring this country has a thriving, clean growth economy that protects the environment and promotes the well-being of all Canadians.
Upvote Downvote

Capital Forensics, Inc. Promotes Robert Valker to Managing Director

2016-01-19 prnewswire
ARLINGTON HEIGHTS, Ill., Jan. 19, 2016 /PRNewswire/ -- Capital Forensics, Inc. (CFI), the leader in expert...
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...